The U.S. Food and Drug Administration announced on October 1, 2026, that it approved the Autus Size-Adjustable Valve for pediatric patients with congenital pulmonary valve disease. The size-adjustable heart valve is surgically implanted and designed to be expanded later as a child grows. According to the FDA, it may reduce the need for repeat open-heart surgeries.
The FDA approval announcement describes two firsts: a heart valve designed for expansion after surgery to accommodate growth, and the first U.S.-approved heart valve using polymeric material rather than animal-derived tissue for its leaflets.
How the size-adjustable heart valve works
The Autus valve can initially be implanted at approximately 13 millimeters in diameter, a size the FDA describes as suitable for a toddler or preschool-aged child. It can later be widened using a balloon catheter, a small inflatable tube, to reach up to 22 millimeters—comparable to an adult-sized pulmonary valve.
The device does not grow automatically. Its design allows expansion after implantation. This distinction matters because the potential benefit is accommodating a child’s growth without replacing the valve through another open-heart operation.
The valve’s leaflets—the inner flaps that open and close to control blood flow—are made from polymeric material. The FDA says animal-derived tissue used in traditional valves tends to harden and break down faster in children. One-year follow-up data suggest the Autus valve’s synthetic leaflets hold up well, although longer-term research continues.
Who may be affected by the approval?
The approval concerns children with congenital pulmonary valve disease who need pulmonary valve replacement. Pulmonary valve stenosis involves a narrowed valve, while pulmonary valve atresia involves a valve that does not form normally. Both can restrict blood flow from the heart to the lungs.
The FDA reports that congenital heart defects affect about one in every 100 U.S. births. Citing the Centers for Disease Control and Prevention, the announcement says pulmonary valve atresia and stenosis together affect approximately 4,200 babies in the United States each year.
Some children may have significant pulmonary regurgitation, or backward leakage through the valve, after treatment for these defects. Over time, that leakage can weaken or enlarge the right ventricle and create a need for valve replacement. The announcement does not describe this device as an option for every congenital heart defect.
What the clinical study found
The FDA based its approval on a study enrolling 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients had acceptable blood-flow performance through the right side of the heart and no more than mild leakage through the valve.
All study patients had a successful procedure. The FDA reported no deaths, strokes, blood clots requiring additional treatment, or other clot-related complications. Three patients experienced valve-frame fractures, and two had reduced movement of one leaflet. None of those events caused symptoms.
Valve performance began deteriorating in two patients who started to outgrow the device. Both valves were successfully expanded without an invasive surgical procedure. However, the FDA emphasized that experience with expansion is limited. Longer-term studies are examining risks and whether expansion can maintain valve function and reduce surgical procedures.
Approval and the official notice
The device received approval through the FDA’s premarket approval pathway, its most stringent medical-device marketing application process. Edwards Lifesciences received approval for the valve, which was developed by Autus Valve Technologies Inc.
The announcement provides no patient-specific safety instructions or treatment plan. Readers seeking the agency’s exact description of the approved use, study findings, reported device issues, and evidence limitations should consult the linked official notice. Related coverage is available in our explainer on the first size-adjustable heart valve for children.
Frequently Asked Questions
Does the valve grow on its own?
No. It is designed to be widened after implantation using a balloon catheter as a child grows.
Does it eliminate future heart surgery?
The FDA says it may reduce repeat open-heart surgeries. The announcement does not establish that it eliminates them.
What remains uncertain?
Experience with valve expansion is limited. Longer-term studies are evaluating risks, valve function after expansion, and the potential to reduce surgical procedures.
